<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1893">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537757</url>
  </required_header>
  <id_info>
    <org_study_id>P08535</org_study_id>
    <secondary_id>MK-8931-009</secondary_id>
    <nct_id>NCT01537757</nct_id>
  </id_info>
  <brief_title>A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])</brief_title>
  <official_title>An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (Protocol No. MK-8931-009 [P08535])</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics of MK-8931, a ß-secretase inhibitor, in&#xD;
      participants with renal insufficiency. In Part 1 of the study, pharmacokinetics of MK-8931 in&#xD;
      participants with severe renal disease and in healthy matched control participants will be&#xD;
      studied. If data from Part 1 confirms that severe renal impairment does not alter the&#xD;
      pharmacokinetics of MK-8931 to the extent requiring dosage adjustment, then no further study&#xD;
      will be required and Part 2 will be optional. If the data does not support this conclusion,&#xD;
      then Part 2 will be conducted to study the pharmacokinetics of MK-8931 in participants with&#xD;
      moderate and mild renal impairment compared to healthy matched controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of MK-8931</measure>
    <time_frame>Predose through 120 hours post single dose of MK-8931</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLr) of MK-8931</measure>
    <time_frame>Predose through 120 hours post single dose of MK-8931</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of MK-8931 dose excreted in urine (fe)</measure>
    <time_frame>Predose through 120 hours post single dose of MK-8931</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Part 1, Panel A - Severe Renal Impairment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Panel B - Healthy Control Group to Match Panel A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Panel C - Moderate Renal Impairment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Panel D - Healthy Control Group to Match Panel C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Panel E - Mild Renal Impairment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Panel F - Healthy Control Group to Match Panel E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8931</intervention_name>
    <description>Single dose, administered as oral capsules</description>
    <arm_group_label>Part 1, Panel A - Severe Renal Impairment Group</arm_group_label>
    <arm_group_label>Part 1, Panel B - Healthy Control Group to Match Panel A</arm_group_label>
    <arm_group_label>Part 2, Panel C - Moderate Renal Impairment Group</arm_group_label>
    <arm_group_label>Part 2, Panel D - Healthy Control Group to Match Panel C</arm_group_label>
    <arm_group_label>Part 2, Panel E - Mild Renal Impairment Group</arm_group_label>
    <arm_group_label>Part 2, Panel F - Healthy Control Group to Match Panel E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index ≤39 kg/m^2&#xD;
&#xD;
          -  No clinically significant abnormality on electrocardiogram&#xD;
&#xD;
          -  Female participant must be postmenopausal or surgically sterilized&#xD;
&#xD;
          -  Non-vasectomized men must agree to use a condom with spermicide or abstain from sexual&#xD;
             intercourse, during the trial and for 3 months after stopping the medication&#xD;
&#xD;
        Inclusion Criteria Specific to Renally Impaired Participants:&#xD;
&#xD;
          -  Clinical diagnosis of renal insufficiency based on Estimated Glomerular Filtration&#xD;
             rate (eGFR): severely decreased eGFR, defined as &lt;30 mL/min/1.73m^2 and participant is&#xD;
             not on dialysis; moderately decreased eGFR, defined as ≥30 to &lt;60 mL/min/1.73m^2;&#xD;
             mildly decreased eGFR, defined as ≥60 to &lt;80 mL/min/1.73m^2&#xD;
&#xD;
          -  Stable baseline health based on medical history, physical examination, vital signs,&#xD;
             and laboratory tests&#xD;
&#xD;
        Inclusion Criterion Specific to Healthy Participants:&#xD;
&#xD;
          -  eGFR ≥80 mL/min/1.73m^2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of any drug, including history or presence of&#xD;
             inflammatory bowel disease, gastrointestinal or rectal bleeding; presence of active&#xD;
             ulcer; history of major gastrointestinal tract surgery such as gastrectomy,&#xD;
             gastroenterostomy, or bowel resection; history of pancreatic injury or pancreatitis;&#xD;
             history or presence of liver disease or liver injury; history of urinary obstruction&#xD;
             or difficulty in voiding&#xD;
&#xD;
          -  History of any infectious disease within 4 weeks prior to drug administration&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies (HCV) or&#xD;
             human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  History of risk factors for Torsades de Pointes (e.g., heart failure/cardiomyopathy or&#xD;
             family history of Long QT Syndrome)&#xD;
&#xD;
          -  Participant has had a kidney removed or has a functioning renal transplant&#xD;
&#xD;
          -  History of alcohol or drug abuse in the past 2 years&#xD;
&#xD;
          -  Blood donation or loss of significant volume of blood in the past 60 days prior to&#xD;
             dosing&#xD;
&#xD;
          -  Previously received MK-8931&#xD;
&#xD;
          -  History of significant multiple and/or severe allergies (including latex allergy), or&#xD;
             anaphylactic reaction or significant intolerability to prescription or&#xD;
             non-prescription drugs or food&#xD;
&#xD;
          -  History of malignancy occurring within the 5 years immediately before screening,&#xD;
             except for a participant who has been adequately treated for basal cell or squamous&#xD;
             cell skin cancer; or in situ cervical cancer; or&#xD;
&#xD;
        localized prostate carcinoma; or has undergone potentially curative therapy with no&#xD;
        evidence of recurrence ≥1 year post-therapy&#xD;
&#xD;
        Exclusion Criteria Specific to Renally Impaired Participants:&#xD;
&#xD;
          -  Rapidly fluctuating renal function as determined by historical measurements&#xD;
&#xD;
          -  Suspected renal artery stenosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>January 23, 2015</last_update_submitted>
  <last_update_submitted_qc>January 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

